{"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_topology","feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","contains":"claims, sources, anecdotes, question_graph slice","slug":"retatrutide-glp1-gut","urls":{"read":"https://miscsubjects.com/api/articles/retatrutide-glp1-gut/topology"},"how_to_use":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/retatrutide-glp1-gut/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/retatrutide-glp1-gut/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"graph_topology","name":"Cross-article graph","what":"Merged claims/sources across condition+stack slugs for one question.","urls":{"read":"https://miscsubjects.com/api/articles/retatrutide-glp1-gut/graph-topology?question=..."}},{"id":"question_graph","name":"Question graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output).","urls":{"read":"https://miscsubjects.com/api/articles/retatrutide-glp1-gut/question-graph","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/retatrutide-glp1-gut/voxels","write":"https://miscsubjects.com/api/protocol/claim"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","why":"Every feature is auditable collective intelligence","how":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/retatrutide-glp1-gut/topology"},"imessage":null,"router":null,"related":[{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"graph_topology","what":"Merged claims/sources across condition+stack slugs for one question."},{"id":"question_graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output)."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."}],"not_medical_advice":true},"slug":"retatrutide-glp1-gut","title":"Retatrutide for GLP-1 Gut Damage: Weight Loss Pathways vs Gastric Slowing Evidence","register":"source_ledger","tags":["peptide","matrix"],"updated_at":"2026-07-17T02:41:17.200Z","body_excerpt":"## What's breaking down if you have GLP-1 gut damage / gastroparesis\n\nIf GLP-1 agonists have slowed your gastric emptying, the core issue is delayed stomach emptying. Food stays longer in the stomach. This leads to nausea, bloating, early fullness, and sometimes vomiting. The mechanism is the GLP-1 pathway itself, which slows motility to reduce calorie intake. No tissue breakdown like disc degeneration occurs here. Instead, the drug action directly affects gut motility. Rapid weight loss from these drugs can also reduce muscle mass, which may compound metabolic issues over time. The condition persists if the slowing effect continues without dose adjustment or cessation.\n\n## Why Retatrutide might help you\n\n1. You are reading about **GLP-1 gut damage / gastroparesis** — what breaks down matters before any compound name.\n2. **What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\n3. **What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\n4. **Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\nRetatrutide activates GLP-1, GIP, and glucagon receptors. This triple action drives greater weight reduction than single or dual agonists in phase 2 data. If excess weight adds mechanical stress elsewhere in your body, the resulting loss could ease that load. However, retatrutide also delays gastric emptying via its GLP-1 component. This is the same pathway linked to gastroparesis symptoms in the class. For someone already experiencing GLP-1 gut damage, the weight loss benefit sits alongside the risk of further or prolonged motility slowing. No direct repair of damaged gut motility is shown.\n\n## Why GLP-1 agonists (class) matters for you\n\n**Drug:** GLP-1 agonists (class)\n**What it does:** Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss.\n**Therefore for you:** This drug reduces load through weight loss and supports metabolism but suppresses gastric motility signals, which trades off repair potential for your gut condition by extending the slowing effect.\n\nGLP-1 agonists deliver metabolic improvements including appetite reduction and better glucose control. These come with the known tradeoff of slowed gastric emptying. In people with existing symptoms, this can worsen or prolong gastroparesis-like effects. Muscle loss during fast weight drop may further affect overall repair capacity. The class supports metabolic repair pathways while directly contributing to the motility issue central to your described condition.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **Retatrutide** → metabolic load / body weight\n\nRetatrutide combines weight-loss driven load reduction with the same GLP-1 gut-slowing mechanism found in the broader agonist class. The metabolic benefit layer may ease body-wide mechanical stress if weight is a factor. The gut layer remains a direct class effect rather than a fix. No synergy for reversing existing gastroparesis is described; the compound aligns with the drug class profile.\n\n## What the evidence actually shows\n\nHuman trials (phase 2) report gastrointestinal side effects including nausea, vomiting, diarrhea, and constipation in retatrutide groups, higher than placebo and often during dose escalation. One study specifically measured delayed gastric emptying with retatrutide. No serious GI disorders such as gastroparesis or bowel obstruction appeared in the reported trial data. Population studies on the GLP-1 class show elevated risk of gastroparesis diagnosis (around 3.67 times higher in one analysis of weight-loss users). Preclinical data confirm gastric emptying delay in animal models. No human trials test re","ranking":"safety-first (interaction_risk/limitations), then quote-gated effective_weight","claims":[{"id":"c1","text":"Retatrutide delays gastric emptying in human studies","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s1"],"source_status":"sourced","why_material":"Directly relevant to gastroparesis risk in GLP-1 context","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c2","text":"Phase 2 trials show GI side effects higher with retatrutide than placebo","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s2"],"source_status":"sourced","why_material":"Establishes side effect profile matching class","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c3","text":"GLP-1 class linked to 3.67x higher gastroparesis risk in population study","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s3"],"source_status":"sourced","why_material":"Context for retatrutide as triple agonist","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c4","text":"No serious gastroparesis reported in retatrutide trials","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s4"],"source_status":"sourced","why_material":"Limits claims of severe harm in studied populations","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c5","text":"Reddit users report gastroparesis symptoms at low retatrutide doses","tier":"anecdotal","weight":0.3,"section":"What people say on Reddit","slot":null,"interaction_risk":false,"status":"active","source_ids":["s5"],"source_status":"sourced","why_material":"Real-world reports beyond trials","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/37311727/","title":"The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying","quote":"retatrutide delays gastric emptying","summary":"Phase 1/2 study measuring gastric emptying delay with retatrutide","claim_ids":["c1"],"link_status":"ok","quote_status":"verified","hash":"03ad663c6225b0d33824c5b05ecdc2c17270d03ae81025891037f55ee83a8ca7"},{"id":"s2","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12026077/","title":"Efficacy and safety of retatrutide","quote":"Gastrointestinal side effects such as diarrhea, vomiting, and constipation had a higher incidence in the retatrutide groups","summary":"Safety data from retatrutide trials","claim_ids":["c2"],"link_status":"ok","quote_status":"verified","hash":"5cf94403bfcbefd3349cd2a57945a09002bbb77141e6cb4b10661614efe2ffc4"},{"id":"s3","type":"news","url":"https://www.med.ubc.ca/news/weight-loss-drugs-linked-to-stomach-paralysis-other-serious-gastrointestinal-conditions/","title":"Weight-loss drugs linked to stomach paralysis","quote":"3.67 times higher risk of gastroparesis","summary":"UBC study on GLP-1 agonists and GI risks","claim_ids":["c3"],"link_status":"ok","quote_status":"verified","hash":"6a51f9ece064dbd95425a613a71da524978e0d88587a8189e768082a991f9a7e"},{"id":"s4","type":"news","url":"https://mdedge.com/endocrinology/article/272111/obesity/retatrutide-produces-greatest-weight-loss","title":"Retatrutide Produces Greatest Weight Loss","quote":"no serious GI disorders, such as bowel obstruction or gastroparesis, were reported in any of the 26 trials","summary":"Review of incretin trial safety data","claim_ids":["c4"],"link_status":"ok","quote_status":"verified","hash":"94cff04d432c3c86eefcc1c08974243424e26e75d4cc925d77e110084e1ec3f3"},{"id":"s5","type":"reddit","url":"https://www.reddit.com/r/Retatrutide/comments/1k1mq3e/gastroparesis_on_low_dose/","title":"Gastroparesis on low dose?","quote":"In my case, it's pure gastroparesis (slowed gastric emptying), which is a known effect of retatrutide","summary":"User report of symptoms at low dose","claim_ids":["c5"],"link_status":"ok","quote_status":"unverified","hash":"c3e708760498246fa256c4c47a436a5037e7e09624c9847e1d4adc2e305e7332"}],"anecdotal_sources":[{"id":"s5","type":"reddit","url":"https://www.reddit.com/r/Retatrutide/comments/1k1mq3e/gastroparesis_on_low_dose/","title":"Gastroparesis on low dose?","quote":"In my case, it's pure gastroparesis (slowed gastric emptying), which is a known effect of retatrutide","summary":"User report of symptoms at low dose","claim_ids":["c5"],"link_status":"ok","quote_status":"unverified","hash":"c3e708760498246fa256c4c47a436a5037e7e09624c9847e1d4adc2e305e7332"}],"scientific_sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/37311727/","title":"The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying","quote":"retatrutide delays gastric emptying","summary":"Phase 1/2 study measuring gastric emptying delay with retatrutide","claim_ids":["c1"],"link_status":"ok","quote_status":"verified","hash":"03ad663c6225b0d33824c5b05ecdc2c17270d03ae81025891037f55ee83a8ca7"},{"id":"s2","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12026077/","title":"Efficacy and safety of retatrutide","quote":"Gastrointestinal side effects such as diarrhea, vomiting, and constipation had a higher incidence in the retatrutide groups","summary":"Safety data from retatrutide trials","claim_ids":["c2"],"link_status":"ok","quote_status":"verified","hash":"5cf94403bfcbefd3349cd2a57945a09002bbb77141e6cb4b10661614efe2ffc4"}],"user_reports":[],"related_articles":[],"question_graph":{"slug":"retatrutide-glp1-gut","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"honesty":{"active_claims":5,"retracted_claims":0,"cut_claims":0,"challenges":0,"scrub_events":0,"note":"Retracted/cut claims stay on ledger but are excluded from ask unless ?include_inactive=1"},"counts":{"claims":5,"claims_total":5,"sources":5,"anecdotal":1,"scientific":2,"user_reports":0,"questions":0,"evidence_ingests":0}}